FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143399650> ?p ?o ?g. }

• W2143399650 endingPage "1233" @default.
• W2143399650 startingPage "1227" @default.
• W2143399650 abstract "Capecitabine is a rationally designed oral, tumor-activated fluoropyrimidine carbamate with high activity in metastatic breast cancer. This multicenter phase II study was designed to evaluate further the efficacy and safety of capecitabine in patients with metastatic breast cancer previously treated with a taxane-containing regimen.All patients had to have documented progression after paclitaxel- or docetaxel-containing chemotherapy. Treatment comprised 3-week cycles of oral capecitabine 1250 mg/m(2) twice-daily for 14 days followed by a 7-day rest period.One hundred and thirty-six patients were enrolled. Disease stabilization occurred in 63 patients (46%) and the overall response rate was 15% (95% confidence interval 10% to 23%), providing an overall tumor control rate of 62%. Median time to progression was 3.5 months, median duration of response was 7.5 months and median overall survival was 10.1 months. Capecitabine was generally well-tolerated: most treatment-related adverse events were grade 1/2 in intensity; grade 3/4 treatment-related adverse events were hand-foot syndrome (13%), diarrhea (8%), vomiting (4%) and nausea (3%). There were no treatment-related deaths.This study confirms that capecitabine achieves a high tumor control rate in heavily pretreated patients with metastatic breast cancer. Due to its favorable safety profile and convenient oral administration, capecitabine can be given as an outpatient therapy. Capecitabine should be considered the reference treatment in this setting based on consistently high efficacy and good tolerability." @default.
• W2143399650 created "2016-06-24" @default.
• W2143399650 creator A5011410319 @default.
• W2143399650 creator A5016141312 @default.
• W2143399650 creator A5020322058 @default.
• W2143399650 creator A5022971855 @default.
• W2143399650 creator A5035387502 @default.
• W2143399650 creator A5042395170 @default.
• W2143399650 creator A5047836442 @default.
• W2143399650 creator A5048170384 @default.
• W2143399650 creator A5052081262 @default.
• W2143399650 creator A5066710773 @default.
• W2143399650 creator A5076155394 @default.
• W2143399650 creator A5078248078 @default.
• W2143399650 date "2003-08-01" @default.
• W2143399650 modified "2023-10-14" @default.
• W2143399650 title "Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy" @default.
• W2143399650 cites W1828283074 @default.
• W2143399650 cites W1939003096 @default.
• W2143399650 cites W2009930501 @default.
• W2143399650 cites W2015159040 @default.
• W2143399650 cites W2039310969 @default.
• W2143399650 cites W2044647580 @default.
• W2143399650 cites W2044970916 @default.
• W2143399650 cites W2077637101 @default.
• W2143399650 cites W2089514388 @default.
• W2143399650 cites W2099658604 @default.
• W2143399650 cites W2123732467 @default.
• W2143399650 cites W2131770017 @default.
• W2143399650 cites W2138926750 @default.
• W2143399650 cites W2141616721 @default.
• W2143399650 doi "https://doi.org/10.1093/annonc/mdg346" @default.
• W2143399650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12881384" @default.
• W2143399650 hasPublicationYear "2003" @default.
• W2143399650 type Work @default.
• W2143399650 sameAs 2143399650 @default.
• W2143399650 citedByCount "225" @default.
• W2143399650 countsByYear W21433996502012 @default.
• W2143399650 countsByYear W21433996502013 @default.
• W2143399650 countsByYear W21433996502014 @default.
• W2143399650 countsByYear W21433996502015 @default.
• W2143399650 countsByYear W21433996502016 @default.
• W2143399650 countsByYear W21433996502017 @default.
• W2143399650 countsByYear W21433996502018 @default.
• W2143399650 countsByYear W21433996502019 @default.
• W2143399650 countsByYear W21433996502020 @default.
• W2143399650 countsByYear W21433996502021 @default.
• W2143399650 countsByYear W21433996502022 @default.
• W2143399650 countsByYear W21433996502023 @default.
• W2143399650 crossrefType "journal-article" @default.
• W2143399650 hasAuthorship W2143399650A5011410319 @default.
• W2143399650 hasAuthorship W2143399650A5016141312 @default.
• W2143399650 hasAuthorship W2143399650A5020322058 @default.
• W2143399650 hasAuthorship W2143399650A5022971855 @default.
• W2143399650 hasAuthorship W2143399650A5035387502 @default.
• W2143399650 hasAuthorship W2143399650A5042395170 @default.
• W2143399650 hasAuthorship W2143399650A5047836442 @default.
• W2143399650 hasAuthorship W2143399650A5048170384 @default.
• W2143399650 hasAuthorship W2143399650A5052081262 @default.
• W2143399650 hasAuthorship W2143399650A5066710773 @default.
• W2143399650 hasAuthorship W2143399650A5076155394 @default.
• W2143399650 hasAuthorship W2143399650A5078248078 @default.
• W2143399650 hasBestOaLocation W21433996501 @default.
• W2143399650 hasConcept C121608353 @default.
• W2143399650 hasConcept C126322002 @default.
• W2143399650 hasConcept C141071460 @default.
• W2143399650 hasConcept C143998085 @default.
• W2143399650 hasConcept C197934379 @default.
• W2143399650 hasConcept C2775930923 @default.
• W2143399650 hasConcept C2776694085 @default.
• W2143399650 hasConcept C2777063308 @default.
• W2143399650 hasConcept C2777511904 @default.
• W2143399650 hasConcept C2777909004 @default.
• W2143399650 hasConcept C2778375690 @default.
• W2143399650 hasConcept C2780580376 @default.
• W2143399650 hasConcept C2781190966 @default.
• W2143399650 hasConcept C2781413609 @default.
• W2143399650 hasConcept C526805850 @default.
• W2143399650 hasConcept C530470458 @default.
• W2143399650 hasConcept C71924100 @default.
• W2143399650 hasConceptScore W2143399650C121608353 @default.
• W2143399650 hasConceptScore W2143399650C126322002 @default.
• W2143399650 hasConceptScore W2143399650C141071460 @default.
• W2143399650 hasConceptScore W2143399650C143998085 @default.
• W2143399650 hasConceptScore W2143399650C197934379 @default.
• W2143399650 hasConceptScore W2143399650C2775930923 @default.
• W2143399650 hasConceptScore W2143399650C2776694085 @default.
• W2143399650 hasConceptScore W2143399650C2777063308 @default.
• W2143399650 hasConceptScore W2143399650C2777511904 @default.
• W2143399650 hasConceptScore W2143399650C2777909004 @default.
• W2143399650 hasConceptScore W2143399650C2778375690 @default.
• W2143399650 hasConceptScore W2143399650C2780580376 @default.
• W2143399650 hasConceptScore W2143399650C2781190966 @default.
• W2143399650 hasConceptScore W2143399650C2781413609 @default.
• W2143399650 hasConceptScore W2143399650C526805850 @default.
• W2143399650 hasConceptScore W2143399650C530470458 @default.
• W2143399650 hasConceptScore W2143399650C71924100 @default.
• W2143399650 hasIssue "8" @default.

• next